The state of Mississippi has also won a remand of its lawsuit accusing Fresenius USA Inc. of misleading consumers about the dangers of two dialysis drugs. The Massachusetts federal judge overseeing multidistrict litigation (MDL), as he did in the Louisiana case, found the state’s presence in the suit destroyed diversity jurisdiction. U.S. District Judge Douglas Woodlock remanded the case to state court. The suit, filed on behalf of the state of Mississippi, seeks damages for misleading consumers about the potential of GranuFlo and NaturaLyte to cause sudden cardiac arrest and other issues.
The AG’s suit, which was transferred from Mississippi federal court to be included in the MDL, alleges that the company violated the state’s consumer protection laws by concealing the risks of GranuFlo and Naturalyte dialysis products. The state is seeking up to $10,000 in penalties for each time Fresenius violated the Mississippi Consumer Protection Act by providing false or misleading information to a state resident.
The cases encapsulated in the multidistrict litigation allege that the Plaintiffs or their family members suffered injuries or death after using NaturaLyte or GranuFlo during dialysis, which are designed, manufactured and distributed by Fresenius. According to the suits, the use of these drugs causes an unexpectedly high level of bicarbonate in the blood that can lead to cardiopulmonary arrest or sudden cardiac arrest. Whether the two drugs were defectively designed or manufactured and whether Fresenius provided adequate warnings are central to the suits.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.